STOCK TITAN

SOPHiA GENETICS SA Ordinary Shares - SOPH STOCK NEWS

Welcome to our dedicated page for SOPHiA GENETICS SA Ordinary Shares news (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on SOPHiA GENETICS SA Ordinary Shares stock.

SOPHiA GENETICS SA (Nasdaq: SOPH) is a leader in the field of data-driven medicine, leveraging cutting-edge technology to advance healthcare. Based in Switzerland, the company is renowned for its high medical standards and precision. SOPHiA GENETICS has built the SOPHiA DDM™ Platform, a cloud-based SaaS platform designed to analyze complex genomic and multimodal data, delivering valuable insights for clinical and life sciences research.

Through its innovative platform, SOPHiA GENETICS supports healthcare professionals in over 100 hospitals globally, enabling them to perform faster and more accurate diagnoses using next-generation sequencing (NGS) analytics. The platform also facilitates knowledge sharing within the largest clinical genomics community.

Recently, SOPHiA GENETICS has made significant strides with several notable partnerships:

  • Unilabs, a prominent European diagnostic provider, adopted the SOPHiA DDM™ Platform to enhance their HRD-status testing capabilities in solid tumors.
  • Syndicate Bio in Nigeria integrated MSK-ACCESS® powered by SOPHiA DDM™, marking the first comprehensive genomic profiling and liquid biopsy availability across Africa.
  • Klinikum Klagenfurt in Austria and Instituto Mário Penna in Brazil have also implemented the platform to advance their cancer diagnostics and treatment planning, particularly in blood-related cancers and disorders.

Financially, SOPHiA GENETICS is recognized for its robust operational execution and business momentum, continually reaffirming its guidance. The company is actively collaborating with tech giants like Microsoft and NVIDIA to develop a streamlined whole genome sequencing (WGS) analytical solution, promising rapid and precise insights aiding clinical decision-making.

SOPHiA GENETICS also launched SOPHiA UNITY, a global consortium to accelerate cancer research by harnessing diverse, high-quality data from leading institutions worldwide. The platform’s advanced AI-based technology and proprietary algorithms will support decision-making and expedite oncology research.

For more information, visit SOPHiAGENETICS.com or connect on LinkedIn, X, Facebook, and Instagram.

Rhea-AI Summary

SOPHiA GENETICS (Nasdaq: SOPH) has announced that the Klinikum Klagenfurt am Wörthersee, Austria's third-largest hospital, has implemented the SOPHiA DDM™ Platform. This technology aims to enhance the hospital's next-generation sequencing (NGS) testing and analytical capabilities for both solid tumors and blood cancers. It will assist in providing fast and accurate genomic analysis, aiding data-driven treatment decisions. The hospital's Institute for Laboratory Diagnostics and Microbiology (ILM) serves over half a million patients annually. The platform is expected to streamline data processing, offering reliable insights while conserving resources. This collaboration is set to improve precision medicine and molecular diagnostics at one of Austria's largest laboratories.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
none
-
Rhea-AI Summary

SOPHiA GENETICS, a cloud-native software company, reported Q1 2024 results with a 13% revenue growth to $15.8 million. Gross margins were 65.9% reported and 70.5% adjusted. Operating loss improved by 3% reported and 13% adjusted year-over-year. The company reaffirmed guidance: revenue growth of 25-30%, adjusted gross margin of 72.5-72.7%, and adjusted operating loss of $45-50 million. SOPHiA GENETICS signed debt financing for up to $50 million with Perceptive Advisors to accelerate growth. The company aims to onboard new customers and expand its Liquid Biopsy offering, MSK-ACCESS® powered with SOPHiA DDM™.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
-
Rhea-AI Summary

SOPHiA GENETICS, a cloud-native software company in data-driven medicine, will present at the 2024 RBC Capital Markets Global Healthcare Conference. Chief Financial Officer and Chief Operating Officer, Ross Muken, will speak on May 14, 2024, in New York City.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
conferences
Rhea-AI Summary
SOPHiA GENETICS, a data-driven medicine leader, will announce its Q1 2024 financial results on May 7, 2024. A conference call discussing the results and business outlook will follow, webcast live on their Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
-
Rhea-AI Summary
SOPHiA GENETICS partners with Syndicate Bio to bring MSK-ACCESS® powered with SOPHiA DDM™ to Africa, revolutionizing cancer diagnostics. Syndicate Bio becomes the first lab in Africa to offer comprehensive genomic profiling and liquid biopsy, addressing the underserved healthcare needs in the region. The collaboration aims to advance precision medicine, accelerate drug discovery, and improve cancer treatment outcomes across the continent.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
none
-
Rhea-AI Summary
SOPHiA GENETICS announces Unilabs is using its AI technology to detect Homologous Recombination Deficiency (HRD). Unilabs deploys the SOPHiA DDM™ Platform in Switzerland for cancer diagnostics. HRD is a significant predictor of tumor response to treatment, and SOPHiA GENETICS' AI technology provides fast and accurate results for HRD testing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
AI
Rhea-AI Summary
SOPHiA GENETICS (SOPH) partners with Strand Life Sciences to advance precision medicine globally. The collaboration aims to provide innovative solutions leveraging genomics technologies and bioinformatics services.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.85%
Tags
partnership
-
Rhea-AI Summary
SOPHiA GENETICS partners with Laboratorio Barnafi-Krause in Chile to enhance research capabilities for blood disorders, particularly Chronic Lymphocytic Leukemia (CLL), using advanced AI-powered technology. This collaboration aims to revolutionize diagnostic approaches and treatment strategies for leukemia patients in Chile and Latin America.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
none
-
Rhea-AI Summary
SOPHiA GENETICS partners with University of Saskatchewan to advance research on ovarian cancer care using SOPHiA DDM™ Platform, potentially revolutionizing treatment decisions for ovarian cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.78%
Tags
none
Rhea-AI Summary
SOPHiA GENETICS and UroCCR collaborate on a study using a multimodal algorithm to predict post-operative outcomes for renal cell carcinoma patients. The AI model outperformed usual prognostic scores, showing the potential of AI in cancer research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.94%
Tags
none

FAQ

What is the current stock price of SOPHiA GENETICS SA Ordinary Shares (SOPH)?

The current stock price of SOPHiA GENETICS SA Ordinary Shares (SOPH) is $3.65 as of November 1, 2024.

What is the market cap of SOPHiA GENETICS SA Ordinary Shares (SOPH)?

The market cap of SOPHiA GENETICS SA Ordinary Shares (SOPH) is approximately 241.9M.

What does SOPHiA GENETICS do?

SOPHiA GENETICS is a healthcare technology company that leverages AI to analyze complex genomic and multimodal data, providing insights for clinical diagnostics and life sciences research.

What is the SOPHiA DDM™ Platform?

The SOPHiA DDM™ Platform is a cloud-based SaaS solution that analyzes next-generation sequencing (NGS) data and integrates various diagnostic modalities to deliver actionable insights for healthcare providers.

Where is SOPHiA GENETICS based?

SOPHiA GENETICS is headquartered in Switzerland, with a physical presence in France, the United States, and Brazil.

Who are some of SOPHiA GENETICS' partners?

Recent partners include Unilabs in Europe, Syndicate Bio in Nigeria, Klinikum Klagenfurt in Austria, and Instituto Mário Penna in Brazil.

What is SOPHiA UNITY?

SOPHiA UNITY is a data-driven consortium designed to accelerate cancer research globally by bringing together healthcare institutions to share and analyze diverse, high-quality data.

How does SOPHiA GENETICS support precision medicine?

Through its SOPHiA DDM™ Platform, SOPHiA GENETICS enables healthcare providers to perform fast, accurate genetic analyses, facilitating data-driven treatment decisions and advancing precision medicine.

What recent advancements have SOPHiA GENETICS made?

Recent advancements include the integration of their platform by Unilabs for HRD-testing in tumors, the launch of WGS solutions in collaboration with Microsoft and NVIDIA, and the formation of SOPHiA UNITY for cancer research.

What is the company's mission?

SOPHiA GENETICS' mission is to expand access to data-driven medicine globally, using AI to provide world-class care to patients with cancer and rare disorders.

How does SOPHiA GENETICS ensure data privacy and quality?

The company employs advanced bioinformatics and machine learning technologies to ensure high-quality analysis and secure banking of patient DNA sequence data, maintaining stringent privacy standards.

How can I learn more about SOPHiA GENETICS?

For more information, visit their website at SOPHiAGENETICS.com or connect with them on social media platforms like LinkedIn, X, Facebook, and Instagram.

SOPHiA GENETICS SA Ordinary Shares

Nasdaq:SOPH

SOPH Rankings

SOPH Stock Data

241.89M
65.38M
5.84%
49.85%
0.02%
Health Information Services
Healthcare
Link
United States of America
Rolle